Search Results for "Skin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Skin. Results 401 to 410 of 439 total matches.
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of
cyclosporine
Can prolong the half-life of
chlorpropamide
May increase frequency of skin rash in
patients ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
onchocerciasis (DN
Udall, Clin Infect Dis 2007; 44:53). Skin reactions after ivermectin treatment are often ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Choice of Cephalosporin
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990 (Issue 832)
a cephalosporin. No skin testing materials are available to test for cephalosporin allergy. Other adverse effects ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
occur at the initiation of therapy, such as
headache, skin rash and abdominal discomfort due to
pain ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
with
caution in patients with gastroparesis.
In addition to skin reactions, serious hypersensitivity ...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Two New Intra-Articular Injections for Knee Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
,
tendon rupture, lipoatrophy, skin atrophy, and avascular
necrosis. Systemic adverse effects are also ...
The FDA has approved a single-injection hyaluronic
acid gel (Durolane – Bioventus) and an extended-release
(ER) formulation of the synthetic corticosteroid
triamcinolone acetonide (Zilretta – Flexion) for intra-articular
(IA) treatment of osteoarthritic knee pain.
Drugs for Open-Angle Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
, and an increase
in periorbital skin pigmentation. PGAs may also cause
local irritation, itching, dryness ...
Glaucoma is a progressive optic neuropathy
associated with increased intraocular pressure
(IOP; normal range 8-22 mm Hg), which is the only
disease-related factor that can be modified. Topical
drugs that lower IOP are the first line of treatment for
open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8 doi:10.58347/tml.2025.1727a | Show Introduction Hide Introduction
Drugs for Percutaneous Coronary Interventions
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
to frequent skin reactions; it has largely been supplanted by
clopidogrel in the US.
Clinical Trials ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Some Drugs for COVID-19
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
severe disease remains to be established. Lopinavir/ritonavir can cause GI adverse effects, skin ...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
and dysphonia
Systemic absorption has been associated with skin bruising,
cataracts, reduced bone mineral ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction